Table 2.

Identification of SCT-related Risk Factors for Post-SCT CMV Infection

Risk Factor	CMV Reactivation		Total n = 91	P Value
	No n = 65	Yes n = 26
Age
<7 yr	33	10	43	.40
≥7 yr	32	16	48
Disease category
Immunodeficiency	16	3	19	.30
Other	49	23	72
Disease category
Malignant	29	17	46	.10
Other	36	9	45
Donor source
Matched related donor	29	7	36	.20
Other	36	19	55
Donor source
UCB	3	6	9	.01
Other	62	20	82
Donor source
Unrelated donor (cord or marrow)	35	19	54	.20
Matched related donor (marrow)	29	7	36
Donor source
Mismatched unrelated marrow donor	5	2	7	1.00
Matched marrow donor (related or unrelated)	56	18	74
CMV status (recipient/donor)
Pos/pos	17	11	28	.002*
Pos/neg	23	13	36
Neg/pos	25	1	26
Pos/ind	0	1	1
CMV status (recipient/donor)
Pos/pos	17	11	28	.80
Pos/neg	23	13	36
CMV status (recipient/donor)
Pos/pos	17	11	28	.002
Neg/pos	25	1	26
Recipient CMV status
Pos	40	25	65	.0006
Neg	25	1	26
Donor CMV status
Pos	42	12	36	.20
Neg	23	13	54
Receipt of TBI
Yes	25	9	34	.80
No	40	17	57
History of CMV before transplantation
Yes	2	4	6	.053
No	63	22	85
Reduced-intensity regimen
Yes	9	1	10	.30
No	56	25	81
ATG use in conditioning
Yes	18	6	24	.80
No	47	20	67
Alemtuzumab use in conditioning
Yes	7	2	9	1.00
No	58	24	82
Fludarabine use in conditioning
Yes	26	8	34	.50
No	39	18	57
ATG, alemtuzumab, or fludarabine use in conditioning
Yes	34	12	46	.60
No	31	14	45
Steroid exposure within day +50 after transplantation
Yes	29	16	45	.20
No	36	10	46
Acute GVHD
Yes	6	7	13	.04
No	59	19	78
Neutrophil engraftment within day 21
Yes	28	14	42	.40
No	37	12	49

TBI indicates total body irradiation.

P value of Fisher’s exact test.

^*One patient with “positive/indeterminate” (positive recipient but indeterminate donor serostatus) was not included in the Fisher’s exact test.